• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    4D Molecular Therapeutics Inc (NQ: FDMT )

    8.120 -0.160 (-1.93%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about 4D Molecular Therapeutics Inc

    < Previous 1 2 3 Next >
    4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
    Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation 
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    4DMT Announces Presentations at Upcoming Retina Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in the 2024 Cantor Global Healthcare Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
    • 24-week injection-free subgroup analyses from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden... 
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in Upcoming Investor Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Announces Presentations at ARVO 2024 Annual Meeting
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Reports Full Year 2023 Financial Results and Operational Highlights
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.